particularly NicOx's naproxcinod.
Auj. à 06:13
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
* Feb 25, 2010 à 1:21 PM
With several recent non-approvable decisions in the osteoarthritis market since 2006, It has updated its forecast to account for the effect on the market. We have revised the market outlook over the next 10 years using the latest IMS data. We expect the market to grow steadily, with a CAGR from 2007 to 2017 of 3.2%, to reach sales of nearly $5.5 billion in 2017.
Scope of this report
*
This report gives a strategic analysis of the likely impact that recent events will have on the osteoarthritis market
*
Includes osteoarthritis-specific and total brand sales forecasts for the key brands in the seven major markets to 2017
*
This report provides a global market snapshot by including osteoarthritis-specific sales analysis for leading brands outside the seven major markets
*
This report includes updated forecasts of nearly 130 currently marketed products and reassesses pipeline product launch dates and sales forecasts
Research and analysis highlights
After three years of decline, market sales grew by 0.8% (2006-07) to reach $4 billion in the 7MM in 2007. Driving growth was an increase in sales of COX-2, non-narcotic analgesic and corticosteroid classes. Market sales will reach $5.5 billion by 2017 (3.2% CAGR) boosted by pipeline product launches, particularly NicOx's naproxcinod.